Barclays Maintains Overweight on Omada Health, Raises Price Target to $20

Benzinga Newsdesk www.benzinga.com Positive 74.5%

Neg 0% Neu 0% Pos 74.5%

Barclays analyst Saket Kalia maintains Omada Health (NASDAQ:OMDA) with a Overweight and raises the price target from $18 to $20.